White Papers
How to file your Marketing Authorization the right way
Avoid those 6 common mistakes and file a successful Marketing Authorization with the EMA.
Get 25 years of expert advice in this White Paper
A practical guide for first-time biopharma applicants entering the EU market.
Filing for EMA marketing authorisation is complex—especially for companies navigating it for the first time. This guide explores six frequent missteps that can delay or jeopardize approval.
What you'll learn:
-
Why early engagement with EMA and local agencies is non-negotiable
-
How misunderstanding centralized procedures can derail timelines
-
What a complete, high-quality dossier should look like
-
The benefits of early Orphan/PRIME designation
-
Why planning for realistic timelines and PIP compliance is essential
Each section includes real-world examples, EMA references, and practical tips to help regulatory and strategic teams improve their chances of a smooth, successful submission.
Access our White Paper
Discover our latest news
Expert Q&As
First interactions with EMA - Q&A 4
What is a Pediatric Investigation Plan (PIP) and when should we plan for it in Europe?
Expert Q&As
First interactions with EMA - Q&A 6
What CMC (Chemistry, Manufacturing, and Controls) expectations in the EU might surprise biopharma companies?
Expert Q&As
First interactions with EMA - Q&A 3
Why is early engagement with EMA, payers, KOLs, and patient groups so important?
